Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Boston Scientific (BSX)

Boston Scientific Reports Third Quarter 2026 Financial Results and Guidance

Mixed Impact 4 of 5 earnings

Boston Scientific Corporation announced its third quarter 2026 financial results, reporting net sales of $5.138 billion, a 1.5 percent increase compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, while adjusted EPS reached $0.73.

Key points

  • Generated third quarter 2026 net sales of $5.138 billion, up 1.5 percent reported, operational, and organic year-over-year.
  • Reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, and adjusted EPS of $0.73.
  • Estimated full-year 2026 organic net sales growth of approximately 3.75 percent and adjusted EPS of $3.16 to $3.18.

The filing

CompanyBoston Scientific (BSX)
Form8-K, current report
Filed with the SECOct 28, 2026, 6:34 AM ET
Accession number0000885725-26-000066

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Oct 29, 2026, 3:00 AM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.